Skip to main content

AMORIScancer: Metabolic Profiles and Cancer

The aim of this project is to examine the role of metabolic markers in the risk of developing cancer; including glucose, triglycerides, total cholesterol, HDL, LDL, apolipoprotein A-I and B, and GGT.

Project description

Background: There is some evidence that glucose and lipid metabolism influences tumour development. Few observational studies to date have in detail studied associations between metabolic profiles and cancer risk.

Project goals/aims: To examine possible associations between metabolic profiles and cancer risk and prognosis.

Material: The Swedish Apolipoprotein MORtality RISk data-base (AMORIS) includes blood samples from more than 600,000 persons from the Stockholm area between 1985 and 1996. Record linkages have provided additional information on socioeconomic factors, reproductive history, vital status, cancer diagnosis and emigration.

Project leaders

Niklas Hammar

E-post:Niklas.Hammar@ki.se

Göran Wallin

E-post:Goran.Wallin@ki.se

Mats Lambe

Telefon:08-524 861 64

E-post:Mats.Lambe@ki.se

Project period: 2008-ongoing
Main financing: KI Research Funds (M Lambe). The Swedish Cancer Society (N Hammar).

Publications

Lipoprotein components and risk of congestive heart failure in 84,740 men and women in the Apolipoprotein MOrtality RISk study (AMORIS).
Holme I, Aastveit A, Hammar N, Jungner I, Walldius G
Eur. J. Heart Fail. 2009 Nov;11(11):1036-42

Haptoglobin and risk of myocardial infarction, stroke, and congestive heart failure in 342,125 men and women in the Apolipoprotein MOrtality RISk study (AMORIS).
Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G
Ann. Med. 2009 ;41(7):522-32

Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS).
Holme I, Aastveit A, Hammar N, Jungner I, Walldius G
J. Intern. Med. 2009 Dec;266(6):558-70

Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS).
Holme I, Aastveit A, Hammar N, Jungner I, Walldius G
J. Intern. Med. 2009 Feb;265(2):275-87

Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS).
Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G
Atherosclerosis 2010 Nov;213(1):299-305

Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study.
Van Hemelrijck M, Garmo H, Binda E, Hayday A, Karagiannis S, Hammar N, et al
Cancer Causes Control 2010 Oct;21(10):1657-67

Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose.
Van Hemelrijck M, Garmo H, Holmberg L, Walldius G, Jungner I, Hammar N, et al
Cancer 2011 May;117(10):2086-95

Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study.
Van Hemelrijck M, Holmberg L, Garmo H, Hammar N, Walldius G, Binda E, et al
Cancer Epidemiol. Biomarkers Prev. 2011 Mar;20(3):428-37

Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons - the Swedish AMORIS study.
Van Hemelrijck M, Jassem W, Walldius G, Fentiman I, Hammar N, Lambe M, et al
Eur. J. Cancer 2011 Sep;47(13):2033-41

Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study.
Van Hemelrijck M, Walldius G, Jungner I, Hammar N, Garmo H, Binda E, et al
Cancer Causes Control 2011 Jul;22(7):1011-9

High blood hemoglobin concentration as risk factor of major atherosclerotic cardiovascular events in 114,159 healthy men and women in the apolipoprotein mortality risk study (AMORIS).
Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G
Ann. Med. 2012 Aug;44(5):476-86

Gamma-glutamyl transferase and C-reactive protein as alternative markers of metabolic abnormalities and their associated comorbidites: a prospective cohort study.
Melvin JC, Rodrigues C, Holmberg L, Garmo H, Hammar N, Jungner I, et al
Int J Mol Epidemiol Genet 2012 ;3(4):276-85

Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study.
Melvin JC, Seth D, Holmberg L, Garmo H, Hammar N, Jungner I, et al
Cancer Epidemiol. Biomarkers Prev. 2012 Aug;21(8):1381-4

Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study.
Seth D, Garmo H, Wigertz A, Holmberg L, Hammar N, Jungner I, et al
Int J Mol Epidemiol Genet 2012 ;3(2):122-33

The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study.
Van Hemelrijck M, Garmo H, Hammar N, Jungner I, Walldius G, Lambe M, et al
Int. J. Cancer 2012 May;130(9):2118-28

Biomarker-based score to predict mortality in persons aged 50 years and older: a new approach in the Swedish AMORIS study.
Van Hemelrijck M, Harari D, Garmo H, Hammar N, Walldius G, Lambe M, et al
Int J Mol Epidemiol Genet 2012 ;3(1):66-76

Serum calcium and incident and fatal prostate cancer in the Swedish AMORIS study.
Van Hemelrijck M, Hermans R, Michaelsson K, Melvin J, Garmo H, Hammar N, et al
Cancer Causes Control 2012 Aug;23(8):1349-58

Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study.
Wulaningsih W, Garmo H, Holmberg L, Hammar N, Jungner I, Walldius G, et al
J Cancer Epidemiol 2012 ;2012():792034

Country of birth-specific and gender differences in prevalence of diabetes in Sweden.
Carlsson AC, Wändell PE, Hedlund E, Walldius G, Nordqvist T, Jungner I, et al
Diabetes Res. Clin. Pract. 2013 Jun;100(3):404-8

Iron metabolism and risk of cancer in the Swedish AMORIS study.
Gaur A, Collins H, Wulaningsih W, Holmberg L, Garmo H, Hammar N, et al
Cancer Causes Control 2013 Jul;24(7):1393-402

Serum glucose and fructosamine in relation to risk of cancer.
Wulaningsih W, Holmberg L, Garmo H, Zethelius B, Wigertz A, Carroll P, et al
PLoS ONE 2013 ;8(1):e54944

Inorganic phosphate and the risk of cancer in the Swedish AMORIS study.
Wulaningsih W, Michaelsson K, Garmo H, Hammar N, Jungner I, Walldius G, et al
BMC Cancer 2013 May;13():257

Serum calcium and risk of gastrointestinal cancer in the Swedish AMORIS study.
Wulaningsih W, Michaelsson K, Garmo H, Hammar N, Jungner I, Walldius G, et al
BMC Public Health 2013 Jul;13():663